NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that the initial stage of a series of Phase I/II clinical trials of IMC-A12, its anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in children with relapsed or refractory solid malignancies, has commenced patient enrollment. These pediatric trials of IMC-A12 are being carried out by the Children’s Oncology Group (COG), an international research group that consists of more than 240 centers that treat children and adolescents with cancer in the United States, Canada, and other countries.
